Duc M. Giao

Duc M. Giao

Auto-generated profile, based on publicly available information

Duc M. Giao

Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2023 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
JHJiun-Ruey Hu
Jiun-Ruey Hu
DPDae Yong Park
Dae Yong Park
NANikita Agarwal
Nikita Agarwal
MHMatthew Herzig
Matthew Herzig
GOGeorge Ormseth
George Ormseth
SJStephen P. Juraschek
Stephen P. Juraschek

26 July 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DPDane C. Paneitz
Dane C. Paneitz
ABAmeen M. Basha
Ameen M. Basha
AKAntonia van Kampen
Antonia van Kampen
DGDuc Giao
Duc Giao
JTJason Thomas
Jason Thomas
AOAsishana A. Osho
Asishana A. Osho

1 July 2022 in Thyroid®
Verified
Journal Article
Closed access
EBErik Scott Blomain
Erik Scott Blomain
SBScott Berta
Scott Berta
NHNicholas Fackler Hug
Nicholas Fackler Hug
DGDuc M. Giao
Duc M. Giao
AMAntonio Meola
Antonio Meola
EPErqi Liu Pollom
Erqi Liu Pollom
Background: Stereotactic radiosurgery (SRS) is the standard of care for patients with a limited number of brain metastases. Despite the fact that the seminal studies regarding SRS for brain metastases were largely tissue agnostic, several current national guidelines do not uniformly recommend SRS in thyroid cancer. We therefore investigated oncologic outcomes in a cohort of patients with brain metastases from thyroid cancer who received radiotherapy at our institution as well as those in a nationally representative cancer cohort, the national cancer database (NCDB). Methods: We identified patients with thyroid cancer and brain metastases treated with radiotherapy at our institution from 2002 through 2020. For the NCDB cohort, the national database of patients with thyroid cancer was screened on the basis of brain-directed radiotherapy or brain metastases. For the institutional cohort, the cumulative risk of local failure, distant intracranial failure and radiation necrosis were calculated, adjusted for the competing risk of death. Overall survival (OS) in both cohorts was analyzed using Kaplan-Meier method. Univariate analysis was accomplished via clustered competing risks regression. Results: For the institutional cohort, we identified 33 patients with 212 treated brain metastases. Overall survival was 6.6 months. The 1-year cumulative incidences of local failure and distant intracranial failures were 7.0% and 38%, respectively. The 1-year risk of radiation necrosis was 3.3%. In the NCDB cohort, there were 289 patients and median survival was 10.2 months. NCDB national practice patterns analysis showed an increasing use of SRS over time in both the entire cohort and the subset of anaplastic patients. Univariate analysis was performed for overall survival, risk of local failure, risk of regional intracranial failure and risk of radiation necrosis. Conclusions: SRS is a safe, effective and increasingly-utilized treatment for thyroid cancer brain metastases of any histology and should be the standard of care treatment.

4 February 2021 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
Min LangMin Lang
Min Lang
MLM D Li
M D Li
KJK.Z. Jiang
K.Z. Jiang
BYB.C. Yoon
B.C. Yoon
DMD.P. Mendoza
D.P. Mendoza
KBK. Buch
K. Buch
BACKGROUND AND PURPOSE: Severe respiratory distress in patients with COVID-19 has been associated with higher rate of neurologic manifestations. Our aim was to investigate whether the severity of chest imaging findings among patients with coronavirus disease 2019 (COVID-19) correlates with the risk of acute neuroimaging findings. MATERIALS AND METHODS: This retrospective study included all patients with COVID-19 who received care at our hospital between March 3, 2020, and May 6, 2020, and underwent chest imaging within 10 days of neuroimaging. Chest radiographs were assessed using a previously validated automated neural network algorithm for COVID-19 (Pulmonary X-ray Severity score). Chest CTs were graded using a Chest CT Severity scoring system based on involvement of each lobe. Associations between chest imaging severity scores and acute neuroimaging findings were assessed using multivariable logistic regression. RESULTS: Twenty-four of 93 patients (26%) included in the study had positive acute neuroimaging findings, including intracranial hemorrhage (n = 7), infarction (n = 7), leukoencephalopathy (n = 6), or a combination of findings (n = 4). The average length of hospitalization, prevalence of intensive care unit admission, and proportion of patients requiring intubation were significantly greater in patients with acute neuroimaging findings than in patients without them (P < .05 for all). Compared with patients without acute neuroimaging findings, patients with acute neuroimaging findings had significantly higher mean Pulmonary X-ray Severity scores (5.0 [SD, 2.9] versus 9.2 [SD, 3.4], P < .001) and mean Chest CT Severity scores (9.0 [SD, 5.1] versus 12.1 [SD, 5.0], P = .041). The pulmonary x-ray severity score was a significant predictor of acute neuroimaging findings in patients with COVID-19. CONCLUSIONS: Patients with COVID-19 and acute neuroimaging findings had more severe findings on chest imaging on both radiographs and CT compared with patients with COVID-19 without acute neuroimaging findings. The severity of findings on chest radiography was a strong predictor of acute neuroimaging findings in patients with COVID-19.

23 May 2025 in Vascular Medicine
Verified
Journal Article
Closed access
DGDuc M Giao
Duc M Giao
APAlex M Poluha
Alex M Poluha
ESEric A Secemsky
Eric A Secemsky
AKAnna K Krawisz
Anna K Krawisz
Endovascular renal denervation (RDN) is a catheter-based, procedural therapy for the treatment of hypertension that was approved by the US Food and Drug Administration (FDA) in November 2023. Early studies suggest that endovascular RDN reduces blood pressure (BP) in patients with hypertension. However, BP response to RDN is highly variable, optimal patient selection remains uncertain, and the procedure’s high cost remains a significant challenge. The purpose of this review is to comprehensively examine the literature regarding the mechanism by which endovascular RDN reduces BP and the safety and effectiveness of RDN, and to discuss key considerations for selecting appropriate patients for endovascular RDN. Relevant studies in the field were identified from PubMed using search terms including ‘renal denervation’ and ‘renal denervation for hypertension.’ In conclusion, clinical trials have demonstrated a statistically significant BP-lowering effect of endovascular RDN, which based on multiple trials with long-term follow-up, appears to persist over several years with low complication rates. More research is needed to understand which patients benefit most from endovascular RDN and to evaluate the long-term outcomes, including the impact of endovascular RDN on cardiovascular events.

1 September 2026 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
DGDuc M. Giao
Duc M. Giao
PCPedro A. Catarino
Pedro A. Catarino
DEDominic Emerson
Dominic Emerson
KGKambiz Ghafourian
Kambiz Ghafourian
JKJon Kobashigawa
Jon Kobashigawa
LDLaura DiChiacchio
Laura DiChiacchio